Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor.

FAPI SFT radioligand sarcoma theranostic

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 24 07 2023
revised: 07 11 2023
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: aheadofprint

Résumé

Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its potential use as a radiotheranostic target.

Identifiants

DOI: 10.2967/jnumed.123.266411 PMID: 38176718
pubmed: 38176718
pii: jnumed.123.266411
doi: 10.2967/jnumed.123.266411
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Rainer Hamacher (R)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; rainer.hamacher@uk-essen.de.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Kim M Pabst (KM)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Phyllis F Cheung (PF)

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.

Christoph E Heilig (CE)

Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.

Jennifer Hüllein (J)

Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.

Sven-Thorsten Liffers (ST)

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.

Sabrina Borchert (S)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Pedro Fragoso Costa (PF)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Benedikt M Schaarschmidt (BM)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Lukas Kessler (L)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Monika A Miera (MA)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.

Margret Droste (M)

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.

Merve Akbulut (M)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Johanna Falkenhorst (J)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Fadi Zarrad (F)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Karina Kostbade (K)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Ilektra A Mavroeidi (IA)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Hanno Glimm (H)

Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
German Cancer Research Center, Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
German Cancer Consortium, Dresden, Germany; and.

Lale Umutlu (L)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Martin Schuler (M)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Daniel Hübschmann (D)

German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.
Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.

Sebastian Bauer (S)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.

Stefan Fröhling (S)

Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.

Ken Herrmann (K)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Jens T Siveke (JT)

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.

Hans-Ulrich Schildhaus (HU)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Wolfgang P Fendler (WP)

German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.

Classifications MeSH